» Articles » PMID: 12185293

Clinical Studies of Three Oral Prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a Review

Overview
Journal Oncologist
Specialty Oncology
Date 2002 Aug 20
PMID 12185293
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

Although 5-fluorouracil (5-FU) was first introduced in 1957, it remains an essential part of the treatment of a wide range of solid tumors. 5-FU has antitumor activity against epithelial malignancies arising in the gastrointestinal tract and breast as well as the head and neck, with single-agent response rates of only 10%-30%. Although 5-FU is still the most widely prescribed agent for the treatment of colorectal cancer, less than one-third of patients achieve objective responses. Recent research has focused on the biomodulation of 5-FU to improve the cytotoxicity and therapeutic effectiveness of this drug in the treatment of advanced disease. As all the anticancer agents, 5-FU leads to several toxicities. The toxicity profile of 5-FU is schedule dependent. Myelotoxicity is the major toxic effect in patients receiving bolus doses. Hand-foot syndrome (palmar-plantar erythrodysesthesia), stomatitis, and neuro- and cardiotoxicities are associated with continuous infusions. Other adverse effects associated with both bolus-dose and continuous-infusion regimens include nausea and vomiting, diarrhea, alopecia, and dermatitis. All these reasons explain the need for more effective and less toxic fluoropyrimidines. In the first part of this review, we briefly present the metabolic pathways of 5-FU responsible for the efficacy and toxicity of this drug. This knowledge is also necessary to understand the target(s) of biomodulation. The second part is devoted to a review of the literature on three recent prodrugs of 5-FU, i.e., capecitabine, UFT (ftorafur [FTO] plus uracil), and S-1 (FTO plus 5-chloro-2,4-dihydroxypyridine plus potassium oxonate). The pharmacological principles that have influenced the development of these new drugs and our current knowledge of the clinical pharmacology of these new agents, focusing on antitumor activity and toxicity, are presented. The literature was analyzed until March 2002. This review is intended to be as exhaustive as possible since it was conceived as a work tool for readers wanting to go further.

Citing Articles

Cardiotoxicity Associated With a Low Doses of 5-FU Promotes Morphoquantitative Changes in the Intrinsic Cardiac Nervous System.

da Costa Salomao K, da Silva M, Fabiano L, Freitas P, Neves C, Borges S Cardiovasc Toxicol. 2025; 25(2):193-204.

PMID: 39864046 DOI: 10.1007/s12012-024-09958-y.


The Prevalence of 5-Fluorouracil and Capecitabine Cardiotoxicity: A Systematic Review and Meta-Analysis.

Sapapsap B, Thongnoi P, Pongpun A, Kitcharoenpanya S, Todsarot T, Petchsomrit A World J Oncol. 2024; 15(6):902-921.

PMID: 39697430 PMC: 11650610. DOI: 10.14740/wjon1920.


Two-step tandem synthesis of sugar-containing pyrimidine derivatives catalyzed by Lipozyme® TL IM in continuous-flow microreactors.

Xie H, Shao W, Du L, Zhang A, Lin H, Huang Z RSC Adv. 2024; 14(51):38193-38199.

PMID: 39624429 PMC: 11610444. DOI: 10.1039/d4ra07120d.


Association Between Changes in Plasma Capecitabine Concentrations and Adverse Events in the Treatment of Colorectal Cancer.

Hashimoto Y, Yoshida Y, Yamada T, Yoshimatsu G, Yoshimura F, Hasegawa S Cureus. 2024; 16(10):e71341.

PMID: 39534818 PMC: 11555300. DOI: 10.7759/cureus.71341.


PAQR4 oncogene: a novel target for cancer therapy.

Patil D, Raut S, Joshi M, Bhatt P, Bhatt L Med Oncol. 2024; 41(6):161.

PMID: 38767705 DOI: 10.1007/s12032-024-02382-w.